Gain Therapeutics (GANX) Revenue & Revenue Breakdown
Gain Therapeutics Revenue Highlights
Latest Revenue (Y)
$55.18K
Gain Therapeutics Revenue by Period
Gain Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $55.18K | -60.62% |
2022-12-31 | $140.11K | -15.08% |
2021-12-31 | $164.99K | 471.29% |
2020-12-31 | $28.88K | -30.07% |
2019-12-31 | $41.30K | 100.40% |
2018-12-31 | $20.61K | - |
Gain Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $64.80K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | -100.00% |
2023-03-31 | $55.18K | -60.62% |
2022-12-31 | $140.11K | 100.00% |
2022-09-30 | - | -100.00% |
2022-06-30 | $95.10K | 111.31% |
2022-03-31 | $45.01K | 23.84% |
2021-12-31 | $36.34K | 32.90% |
2021-09-30 | $27.34K | -69.33% |
2021-06-30 | $89.17K | 1592.41% |
2021-03-31 | $5.27K | -42.35% |
2020-12-31 | $9.14K | 36.48% |
2020-09-30 | $6.70K | 5.07% |
2020-06-30 | $6.37K | -4.50% |
2020-03-31 | $6.67K | 100.00% |
2019-12-31 | - | -100.00% |
2019-09-30 | $10.32K | - |
2019-06-30 | $10.32K | - |
2019-03-31 | $10.32K | 100.40% |
2018-09-30 | $5.15K | - |
2018-06-30 | $5.15K | - |
2018-03-31 | $5.15K | - |
Gain Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
NAMS | NewAmsterdam Pharma Company | $14.09M | $2.13M |
MOLN | Molecular Partners | $7.04M | $2.74M |
CUE | Cue Biopharma | $5.49M | $3.34M |
INBX | Inhibrx Biosciences | $1.80M | - |
MNOV | MediciNova | $1.00M | - |
TFFP | TFF Pharmaceuticals | $733.87K | $193.39K |
GANX | Gain Therapeutics | $55.18K | - |
ANEB | Anebulo Pharmaceuticals | - | - |
BIVI | BioVie | - | - |
INAB | IN8bio | - | - |
CELC | Celcuity | - | - |
ELVN | Enliven Therapeutics | - | - |
LTRN | Lantern Pharma | - | - |
CSBR | Champions Oncology | - | $-14.06M |